Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep

John C. Morrill, Richard C. Laughlin, Nandadeva Lokugamage, Roberta Pugh, Elena Sbrana, William J. Weise, L. Garry Adams, Shinji Makino, C. J. Peters

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The safety and immunogenicity of two authentic recombinant (ar) Rift Valley fever (RVF) viruses, one with a deletion in the NSs region of the S RNA segment (arMP-12ΔNSs16/198) and the other with a large deletion of the NSm gene in the pre Gn region of the M RNA segment (arMP-12ΔNSm21/384) of the RVF MP-12 vaccine virus were tested in crossbred ewes at 30-50 days of gestation. First, we evaluated the neutralizing antibody response, measured by plaque reduction neutralization (PRNT80), and clinical response of the two viruses in groups of four ewes each. The virus dose was 1×105plaque forming units (PFU). Control groups of four ewes each were also inoculated with a similar dose of RVF MP-12 or the parent recombinant virus (arMP-12). Neutralizing antibody was first detected in 3 of 4 animals inoculated with arMP-12ΔNSm21/384 on Day 5 post inoculation and all four animals had PRNT80 titers of ≥1:20 on Day 6. Neutralizing antibody was first detected in 2 of 4 ewes inoculated with arMP-12ΔNSs16/198 on Day 7 and all had PRNT80 titers of ≥1:20 on Day 10. We found the mean PRNT80 response to arMP-12ΔNSs16/198 to be 16- to 25-fold lower than that of ewes inoculated with arMP-12ΔNSm21/384, arMP-12 or RVF MP-12. No abortions occurred though a single fetal death in each of the arMP-12 and RVF MP-12 groups was found at necropsy. The poor PRNT80 response to arMP-12ΔNSs16/198 caused us to discontinue further testing of this candidate and focus on arMP-12ΔNSm21/384. A dose escalation study of arMP-12ΔNSm21/384 showed that 1×103plaque forming units (PFU) stimulate a PRNT80 response comparable to doses of up to 1×105PFU of this virus. With further study, the arMP-12ΔNSm21/384 virus may prove to be a safe and efficacious candidate for a livestock vaccine. The large deletion in the NSm gene may also provide a negative marker that will allow serologic differentiation of naturally infected animals from vaccinated animals.

Original languageEnglish (US)
Pages (from-to)559-565
Number of pages7
JournalVaccine
Volume31
Issue number3
DOIs
StatePublished - Jan 7 2013

Fingerprint

Rift Valley Fever
Rift Valley fever
Sheep
Vaccines
immune response
ewes
vaccines
Viruses
Safety
sheep
viruses
Neutralizing Antibodies
neutralizing antibodies
gene deletion
dosage
animals
Rift Valley fever virus
RNA
abortion (animals)
Fetal Death

Keywords

  • ArMP-12ΔNSm21/384
  • Rift Valley fever
  • RVF MP-12
  • Sheep

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Morrill, J. C., Laughlin, R. C., Lokugamage, N., Pugh, R., Sbrana, E., Weise, W. J., ... Peters, C. J. (2013). Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine, 31(3), 559-565. https://doi.org/10.1016/j.vaccine.2012.10.118

Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. / Morrill, John C.; Laughlin, Richard C.; Lokugamage, Nandadeva; Pugh, Roberta; Sbrana, Elena; Weise, William J.; Adams, L. Garry; Makino, Shinji; Peters, C. J.

In: Vaccine, Vol. 31, No. 3, 07.01.2013, p. 559-565.

Research output: Contribution to journalArticle

Morrill, JC, Laughlin, RC, Lokugamage, N, Pugh, R, Sbrana, E, Weise, WJ, Adams, LG, Makino, S & Peters, CJ 2013, 'Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep', Vaccine, vol. 31, no. 3, pp. 559-565. https://doi.org/10.1016/j.vaccine.2012.10.118
Morrill JC, Laughlin RC, Lokugamage N, Pugh R, Sbrana E, Weise WJ et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine. 2013 Jan 7;31(3):559-565. https://doi.org/10.1016/j.vaccine.2012.10.118
Morrill, John C. ; Laughlin, Richard C. ; Lokugamage, Nandadeva ; Pugh, Roberta ; Sbrana, Elena ; Weise, William J. ; Adams, L. Garry ; Makino, Shinji ; Peters, C. J. / Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. In: Vaccine. 2013 ; Vol. 31, No. 3. pp. 559-565.
@article{f87e96cc6a38449aa71e5ba436837b4c,
title = "Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep",
abstract = "The safety and immunogenicity of two authentic recombinant (ar) Rift Valley fever (RVF) viruses, one with a deletion in the NSs region of the S RNA segment (arMP-12ΔNSs16/198) and the other with a large deletion of the NSm gene in the pre Gn region of the M RNA segment (arMP-12ΔNSm21/384) of the RVF MP-12 vaccine virus were tested in crossbred ewes at 30-50 days of gestation. First, we evaluated the neutralizing antibody response, measured by plaque reduction neutralization (PRNT80), and clinical response of the two viruses in groups of four ewes each. The virus dose was 1×105plaque forming units (PFU). Control groups of four ewes each were also inoculated with a similar dose of RVF MP-12 or the parent recombinant virus (arMP-12). Neutralizing antibody was first detected in 3 of 4 animals inoculated with arMP-12ΔNSm21/384 on Day 5 post inoculation and all four animals had PRNT80 titers of ≥1:20 on Day 6. Neutralizing antibody was first detected in 2 of 4 ewes inoculated with arMP-12ΔNSs16/198 on Day 7 and all had PRNT80 titers of ≥1:20 on Day 10. We found the mean PRNT80 response to arMP-12ΔNSs16/198 to be 16- to 25-fold lower than that of ewes inoculated with arMP-12ΔNSm21/384, arMP-12 or RVF MP-12. No abortions occurred though a single fetal death in each of the arMP-12 and RVF MP-12 groups was found at necropsy. The poor PRNT80 response to arMP-12ΔNSs16/198 caused us to discontinue further testing of this candidate and focus on arMP-12ΔNSm21/384. A dose escalation study of arMP-12ΔNSm21/384 showed that 1×103plaque forming units (PFU) stimulate a PRNT80 response comparable to doses of up to 1×105PFU of this virus. With further study, the arMP-12ΔNSm21/384 virus may prove to be a safe and efficacious candidate for a livestock vaccine. The large deletion in the NSm gene may also provide a negative marker that will allow serologic differentiation of naturally infected animals from vaccinated animals.",
keywords = "ArMP-12ΔNSm21/384, Rift Valley fever, RVF MP-12, Sheep",
author = "Morrill, {John C.} and Laughlin, {Richard C.} and Nandadeva Lokugamage and Roberta Pugh and Elena Sbrana and Weise, {William J.} and Adams, {L. Garry} and Shinji Makino and Peters, {C. J.}",
year = "2013",
month = "1",
day = "7",
doi = "10.1016/j.vaccine.2012.10.118",
language = "English (US)",
volume = "31",
pages = "559--565",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep

AU - Morrill, John C.

AU - Laughlin, Richard C.

AU - Lokugamage, Nandadeva

AU - Pugh, Roberta

AU - Sbrana, Elena

AU - Weise, William J.

AU - Adams, L. Garry

AU - Makino, Shinji

AU - Peters, C. J.

PY - 2013/1/7

Y1 - 2013/1/7

N2 - The safety and immunogenicity of two authentic recombinant (ar) Rift Valley fever (RVF) viruses, one with a deletion in the NSs region of the S RNA segment (arMP-12ΔNSs16/198) and the other with a large deletion of the NSm gene in the pre Gn region of the M RNA segment (arMP-12ΔNSm21/384) of the RVF MP-12 vaccine virus were tested in crossbred ewes at 30-50 days of gestation. First, we evaluated the neutralizing antibody response, measured by plaque reduction neutralization (PRNT80), and clinical response of the two viruses in groups of four ewes each. The virus dose was 1×105plaque forming units (PFU). Control groups of four ewes each were also inoculated with a similar dose of RVF MP-12 or the parent recombinant virus (arMP-12). Neutralizing antibody was first detected in 3 of 4 animals inoculated with arMP-12ΔNSm21/384 on Day 5 post inoculation and all four animals had PRNT80 titers of ≥1:20 on Day 6. Neutralizing antibody was first detected in 2 of 4 ewes inoculated with arMP-12ΔNSs16/198 on Day 7 and all had PRNT80 titers of ≥1:20 on Day 10. We found the mean PRNT80 response to arMP-12ΔNSs16/198 to be 16- to 25-fold lower than that of ewes inoculated with arMP-12ΔNSm21/384, arMP-12 or RVF MP-12. No abortions occurred though a single fetal death in each of the arMP-12 and RVF MP-12 groups was found at necropsy. The poor PRNT80 response to arMP-12ΔNSs16/198 caused us to discontinue further testing of this candidate and focus on arMP-12ΔNSm21/384. A dose escalation study of arMP-12ΔNSm21/384 showed that 1×103plaque forming units (PFU) stimulate a PRNT80 response comparable to doses of up to 1×105PFU of this virus. With further study, the arMP-12ΔNSm21/384 virus may prove to be a safe and efficacious candidate for a livestock vaccine. The large deletion in the NSm gene may also provide a negative marker that will allow serologic differentiation of naturally infected animals from vaccinated animals.

AB - The safety and immunogenicity of two authentic recombinant (ar) Rift Valley fever (RVF) viruses, one with a deletion in the NSs region of the S RNA segment (arMP-12ΔNSs16/198) and the other with a large deletion of the NSm gene in the pre Gn region of the M RNA segment (arMP-12ΔNSm21/384) of the RVF MP-12 vaccine virus were tested in crossbred ewes at 30-50 days of gestation. First, we evaluated the neutralizing antibody response, measured by plaque reduction neutralization (PRNT80), and clinical response of the two viruses in groups of four ewes each. The virus dose was 1×105plaque forming units (PFU). Control groups of four ewes each were also inoculated with a similar dose of RVF MP-12 or the parent recombinant virus (arMP-12). Neutralizing antibody was first detected in 3 of 4 animals inoculated with arMP-12ΔNSm21/384 on Day 5 post inoculation and all four animals had PRNT80 titers of ≥1:20 on Day 6. Neutralizing antibody was first detected in 2 of 4 ewes inoculated with arMP-12ΔNSs16/198 on Day 7 and all had PRNT80 titers of ≥1:20 on Day 10. We found the mean PRNT80 response to arMP-12ΔNSs16/198 to be 16- to 25-fold lower than that of ewes inoculated with arMP-12ΔNSm21/384, arMP-12 or RVF MP-12. No abortions occurred though a single fetal death in each of the arMP-12 and RVF MP-12 groups was found at necropsy. The poor PRNT80 response to arMP-12ΔNSs16/198 caused us to discontinue further testing of this candidate and focus on arMP-12ΔNSm21/384. A dose escalation study of arMP-12ΔNSm21/384 showed that 1×103plaque forming units (PFU) stimulate a PRNT80 response comparable to doses of up to 1×105PFU of this virus. With further study, the arMP-12ΔNSm21/384 virus may prove to be a safe and efficacious candidate for a livestock vaccine. The large deletion in the NSm gene may also provide a negative marker that will allow serologic differentiation of naturally infected animals from vaccinated animals.

KW - ArMP-12ΔNSm21/384

KW - Rift Valley fever

KW - RVF MP-12

KW - Sheep

UR - http://www.scopus.com/inward/record.url?scp=84871670827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871670827&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.10.118

DO - 10.1016/j.vaccine.2012.10.118

M3 - Article

VL - 31

SP - 559

EP - 565

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -